The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia

Binyan Xu1†, Ziying Zhou2†, Yueting Wen2, Zhongwei Li1, Zhongxi Huang2* and Yuhua Li1,3*

Abstract
The bone marrow microenvironment of acute myeloid leukemia (AML) consists of various cell types and signaling factors, which serve as a niche supporting leukemia cells in their invasion of the human body. However, a systematic landscape of metabolic heterogeneity and its relationship with immunity in the AML microenvironment at single-cell resolution has not yet been established. Herein, we addressed this issue by analyzing 208,543 bone marrow cells from 40 AML patients and 3 healthy donors obtained from GSE130756. We focused on the metabolic preference of AML progenitor cells and diverse immune cells, especially myeloid immune cells and T cells. Accordingly, the immune evasion mechanism of leukemia cells was proposed from the view of the allocation of energy and oxygen, providing a novel direction of treatment. Finally, we tentatively proposed potential targets for AML metabolic therapy, including ENO1, GSTP1, MT-ND4L and UQCR11. Collectively, our analysis facilitates the development of personalized therapies targeting unique immunometabolic profiles.

To the Editor,
Acute myeloid leukemia (AML) is a heterogeneous clonal disease of hematopoietic stem/progenitor cells (HSPCs) characterized by high morbidity, recidivitis and lethality [1]. There is mounting evidence that the variation of the bone marrow microenvironment contributes to the immunosuppression and therapy effect of AML patients [2]. Additionally, metabolic reprogramming and trained immunity have gradually become hot targets in the tumor microenvironment, providing a novel strategy for oncology [3, 4]. Thus, the metabolic regulation of the bone marrow microenvironment in leukemia summarized by our team has been published in Blood Reviews [5]. However, there has been no systematic assessment of how immunity influences metabolism in the leukemia niche.

Herein, we analyzed the normal and AML microenvironments with a total of 208,543 bone marrow cells from 40 AML patients and 3 healthy donors obtained from GSE130756 (Additional file 1: Table S1), which came from a high-throughput and low-cost single-cell RNA platform – Microwell seq. The major cellular components of normal and tumor cellular milieus were detected by constructing the cell atlas according to Wu’s research [6] (Fig. 1a and Additional file 1: Fig. S1a, b).

The metabolic preferences of different cells in AML and normal environments were of particular concern using GSVA. As shown in Fig. 1b, although tumor cells were characterized by rapid proliferation and metastasis [7, 8], energy metabolism was at a relatively low rate compared with that of tumor-infiltrating myeloid immune cells, which obviously increased in the AML bone marrow microenvironment. In contradiction with the Warburg effect [9], oxidative phosphorylation and the tricarboxylic acid cycle were significantly enhanced in immune cells compared with tumor cells. Such a phenomenon provides a new perspective for AML treatment and highlights the importance of trained immunity in AML therapy.

1 Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong, People’s Republic of China
2 Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, People’s Republic of China
Full list of author information is available at the end of the article

†Binyan Xu and Ziying Zhou contributed equally to this work
*Correspondence: zxhuang@smu.edu.cn; liyuhua1974@outlook.com
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
acid cycle are the major energy sources of AML progenitor cells (Fig. 1b). Recent research suggests that leukemia stem cell-enriched primary populations are metabolically dormant and are more dependent on aerobic respiration than glycolysis for energy production [10], which is consistent with our results (Fig. 1b). Surprisingly, amino acid pathways are the main “building blocks” in metabolism microenvironments (Fig. 1c). Moreover, the genes related to metabolic enzymes and the metabolic activity of T cells in the tumor microenvironment (TME) decreased significantly (Additional file 1: Fig. S2a–e). By this token, the existence of AML progenitor cells promotes the formation of the TME, and most immune cells enhance their expression of metabolic genes with leukemia cells, further influencing T cells by decreasing their metabolic genes and disturbing their energy acquisition, resulting in damage to the T-cell killing effect.

It is well known that monocytes can polarize to the M1 or M2 phenotype, with anti-inflammatory or proinflammatory respectively, similar to neutrophils [11]. We successfully distinguished the phenotype of myeloid immune cells and analyzed their polarization ratio (Fig. 1d, Additional file 1: Table S2 and Fig. S3). The results show that the AML bone marrow microenvironment has high levels of myeloid cell infiltration with the increasing proportion of the anti-inflammatory phenotype. Next, we explored the nutrient and oxygen allocation of leukemia cells and tumor-infiltrating immune cells in the TME via GSEA (Additional file 1: Fig. S4–S6). Therefore, we supplemented the AML immune escape mechanism once more. Although myeloid immune cells might be the major energy consumers in the TME, rapidly proliferating leukemia cells deprive them of oxygen, and the hypoxic microenvironment then affects the direction of polarization.

Then, we depicted the communication profile by CellPhoneDB and CellChat. We found that AML progenitor cells prefer to communicate with myeloid immune cells with an immunosuppressive phenotype (Fig. 1e). Moreover, the outgoing and incoming signaling profiles of each cell group were shown, and the signaling pattern in the TME was uncovered (Additional file 1: Fig. S7, S8). Combining the role played by signaling patterns in metabolism (Fig. 1f and Additional file 1: Table S3), leukemia cells affect the metabolic characteristics of immune cells through information communication with surrounding cells, and vice versa. Immune cells can further influence the leukemia under the action of signaling factors, forming a feedback loop in the TME.

Finally, a volcano map, GO terms and PPIs of metabolic differential genes related to AML progenitor cells and HSPCs are shown (Additional file 1: Fig. S9 and Fig. 2a).

We screened 4 metabolic genes with statistical significance related to survival (P < 0.05) ENO1, GSTP1, MT-ND4L and UQCR11, via the GEPIA website (Fig. 2b). ENO1 is associated with glycolysis, but MT-ND4L and UQCR11 are related to oxidative phosphorylation. Moreover, GSTP1 have antitumor effects, and both serve as prognostic indicators for AML patients.

Conclusion

Overall, this study is the first to illustrate the immune evasion mechanism of leukemia cells from the perspective of metabolism, energy, oxygen and immunity of the bone marrow microenvironment by scRNA-seq. Crucially, potential metabolic targets of treatment with clinical significance were proposed (Fig. 2c), which is important for future studies to further explore metabolic treatments for AML. However, our work lacks AML samples for validation, and we need to verify these results in subsequent design experiments.
Fig. 1 (See legend on previous page.)
Fig. 2  

a Biological process and pathway enrichment. The top-scoring pathways related to metabolism and focused on OXPHOS, hinting at the metabolic characteristics of LSCs. 
b Survival analysis of AML metabolic differential genes (P < 0.005). 
c Immune escape mechanism of the AML bone marrow microenvironment. In the AML bone marrow microenvironment, leukemia cells compete with immune cells for nutrients and oxygen. Leukemia cells enhance their metabolic activity to satisfy energy demand. Myeloid immune cells are the major energy consumers and increase their proportions of anti-inflammatory cells, which have close communication with leukemia cells. Moreover, T cells weaken the cytotoxic effect by decreasing their metabolic gene expression levels and have little interaction with tumor cells. Furthermore, ENO1, GSTP1, MT-ND4L and UQCR11 are potential metabolic targets for AML treatment.
Abbreviations
AML: Acute myeloid leukemia; HSPCs: Hematopoietic stem/progenitor cells; GSVA: Gene set variation analysis; GSEA: Gene set enrichment analysis; TME: Tumor microenvironment; GO: Gene ontology; PPIs: Protein–protein interactions.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40164-022-00332-8.

Additional file 1: Table S1. The clinical characteristics of GSE130756.
Table S2. The polarization and anti-inflammatory/pro-inflammatory gene sets of monocytes/neutrophils. Table S3. The relation between signaling pattern and metabolism in the TME. Fig. S1. Verification of the landscape of cell definition. Fig. S2. Heatmaps of gene expression level associated with key metabolic enzymes. Fig. S3. Polarization of myeloid immune cells in microenvironment. Fig. S4. GSEA analysis of insulin pathway and HIF pathway in AML progenitor cells and tumor-infiltrating immune cells. Fig. S5. The metabolic and oxygen preference of different monocyte subtypes in the TME. Fig. S6. The metabolic and oxygen preference of different neutrophil subtypes in the TME. Fig. S7. Cell–cell communications in the TME. Fig. S8. Heatmaps of cytokines communication network in TME. Fig. S9. Exploration of metabolic expression differential gene in AML progenitor cells.

Acknowledgements
Not applicable.

Author contributions
BX and ZZ designed the research, performed the analyses and wrote the paper; YY and ZL help wrote and reviewed the paper, and ZH and YL conducted the research and reviewed the paper. All authors read and approved the final manuscript.

Funding
This work was supported by grants from the National Natural Science Foundation of China (U2001224), the Frontier Research Program of Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory) (2018GZR110105014), the National Natural Science Foundation of China (82100155), the Guangdong Basic and Applied Basic Research Foundation (2019A1515111113), and the Guangdong Basic and Applied Basic Research Foundation (2021A1515110974).

Availability of data and materials
The datasets used and/or analysed during the current study are available in the GEO database.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare no potential competing interests.

Author details
1 Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong, People’s Republic of China. 2 Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, People’s Republic of China. 3 Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510005, People’s Republic of China.

References
1. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood. 2010;116(17):3147–56.
2. Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552–64.
3. Andrejeva G, Rاثmell JC. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors. Cell Metab. 2017;26(1):49–70.
4. Fanucchi S, Dominguez-Andres J, Joosten LAB, Netea MG, Mhlanga MM. The intersection of epigenetics and metabolism in trained immunity. Immunity. 2021;54(1):32–43.
5. Xu B, Hu R, Liang Z, Chen T, Chen J, Hu Y, Jiang Y, Li Y. Metabolic regulation of the bone marrow microenvironment in leukemia. Blood Rev. 2020. https://doi.org/10.1016/j.blre.2020.100786.
6. Wu J, Xiao Y, Sun J, Sun H, Chen H, Zhi Y, Fu H, Yu C, Weigao E, Lai S, et al. A single-cell survey of cellular hierarchy in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):128.
7. Buttunri E, de Prati AC, Boriero D, Mariotto S. Tumor dormancy and interplay with hypoxic tumor microenvironment. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20174305.
8. Li S, Li Q. Cancer stem cells and tumor metastasis (review). Int J Oncol. 2014;44(6):1806–12.
9. Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211–8.
10. Lagadino ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhasuddin M, Ashton JM, Pei S, Grosse V, O’Dwyer K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–41.
11. Giese MA, Hind LE, Huttunen A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159–67.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions